参考文献/References:
[1] Dhanesha N,Joharapurkar A,Shah G,et al．Exendin-4 reduces glycemia by increasing liver glucokinase activity：an insulin independent effect[J]．Pharmacol Rep,2012,64（1）：140-149.
[2] Llewellyn-Smith IJ,Reimann F,Gribble FM,et al．Preproglucagon neurons project widely to autonomic control areas in the mouse brain[J]．Neuroscience,2011,180：111-121.
[3] Tauchi M,Zhang R,D'Alessio DA．Distribution of glucagon-like peptide-1 immunoreactivity in the hypothalamic paraventricular and supraoptic nuclei[J]．J Chem Neuroanat,2008,36（3-4）：144-149.
[4] 梁少双,魏良洲,雪田,等．下丘脑室旁核注射GLP-1对糖尿病大鼠中枢GLP-1受体表达与胃排空的影响[J]．现代生物医学进展,2012,12（8）：1452-1456.
[5] Alhadeff AL,Rupprecht LE,Hayes MR．GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake[J]．Endocrinology,2012,153（2）：647-658.
[6] Sandoval DA,Bagnol D,Woods SC,et al．Arcuate glucagon-like peptide-1 receptors regulate glucose homeostasis but not food intake[J]． Diabetes,2008,57（8）：2046-2054.
[7] Scott MM,Williams KW,Rossi J,et al．Leptin receptor expres-sion in hindbrain GLP-1 neurons regulates food intake and energy balance in mice[J]．J Clin Invest,2011,121（6）：2413-2421.
[8] Seo S,Ju S,Chung H,et al．Acute effects of glucagon-like peptide-1 on hypothalamic neuropeptide and AMP activated kinase expression in fasted rats[J]．Endocr J,2008,55（5）：867-874.
[9] Rüttimann EB,Arnold M,Hillebrand JJ,et al．Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms[J]．Endocrinology,2009,150（3）：1174-1181.
[10] Williams DL,Baskin DG,Schwartz MW．Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety[J]．Endocrinology,2009,150（4）：1680-1687.
[11] Dickson SL,Shirazi RH,Hansson C,et al．The glucagon-like peptide-1（GLP-1）analogue,exendin-4,decreases the rewarding value of food：a new role for mesolimbic GLP-1 receptors[J]．J Neurosci,2012, 32（14）：4812-4820.
[12] Folli F,Guardado Mendoza R．Potential use of exenatide for the treatment of obesity[J]．Expert Opin Investig Drugs,2011,20（12）：1717-1722.
[13] Washington MC,Raboin SJ,Thompson W,et al．Exenatide reduces food intake and activates the enteric nervous system of the gastrointestinal tract and the dorsal vagal complex of the hindbrain in the rat by a GLP-1 receptor[J]．Brain Res,2010,1344：124-133.
[14] Radziszewska E,Bojanowska E．Effects of glucagon-like peptide-1 receptor stimulation and blockade on food consumption and body weight in rats treated with a cannabinoid CB1 receptor agonist WIN 55,212-2[J]．Med Sci Monit Basic Res,2013,19：6-11.
[15] Knauf C,Cani PD,Ait-Belgnaoui A,et al．Brain glucagon-like peptide-1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure[J]．Endocrinology,2008,149（10）：4768-4777.
[16] Cabou C,Campistron G,Marsollier N,et al．Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate,and insulin sensitivity[J]．Diabetes,2008,57（10）：2577-2587.
[17] Nishizawa M,Nakabayashi H,Uehara K,et al．Intraportal GLP-1 stimulates insulin secretion predominantly through the hepatoportal-pancreatic vagal reflex pathways[J]．Am J Physiol Endocrinol Metab, 2013,305（3）：E376-E387.
[18] Baumgartner I,Pacheco-López G,Rüttimann EB,et al．Hepatic-portal vein infusions of glucagon-like peptide-1 reduce meal size and increase c-Fos expression in the nucleus tractus solitarii,area postrema and central nucleus of the amygdala in rats[J]．J Neuroendocrinol,2010, 22（6）：557-563.
[19] Robinson LE,Holt TA,Rees K,et al．Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis[J]．BMJ Open,2013,3（1）：e001986.
[20] Plamboeck A,Veedfald S,Deacon CF,et al．The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty[J]．Am J Physiol Gastrointest Liver Physiol,2013,304（12）：G1117-G1127.
[21] Gu G,Roland B,Tomaselli K,et al．Glucagon-like peptide-1 in the rat brain：distribution of expression and functional implication[J]．J Comp Neurol,2013,521（10）：2235-2261.
[22] Gill A,Hoogwerf BJ,Burger J,et al．Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus：a double-blind,placebo-controlled,randomized pilot study[J]．Cardiovasc Diabetol,2010,9：6.
[23] Okerson T,Yan P,Stonehouse A,et al．Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes[J]．Am J Hypertens,2010,23（3）：334-339.
[24] Halbirk M,Nφrrelund H,Mφller N,et al．Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure[J]．Am J Physiol Heart Circ Physiol,2010,298（3）：H1096-H1102.
[25] Verge D,López X．Impact of GLP-1 and GLP-1 receptor agonists on cardiovascular risk factors in type 2 diabetes[J]．Curr Diabetes Rev,2010,6（4）：191-200.
相似文献/References:
[1]黄婷婷,沈飞霞,谷雪梅.胰高血糖素样肽-1与骨骼肌葡萄糖代谢[J].国际内分泌代谢杂志,2014,(04):281.[doi:10.3760/cma.j.issn.1673-4157.2014.04.019]
Huang Tingting,Shen Feixia,Gu Xuemei..Glucagon-like peptide-1 and glucose metabolism in the skeletal muscle[J].International Journal of Endocrinology and Metabolism,2014,(01):281.[doi:10.3760/cma.j.issn.1673-4157.2014.04.019]
[2]赵荷珺 洪天配.胰高血糖素样肽-1类药物与胰腺安全性[J].国际内分泌代谢杂志,2015,(05):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
Zhao Hejun*,Hong Tianpei..Glucagon-like peptide-1-based therapies and pancreatic safety[J].International Journal of Endocrinology and Metabolism,2015,(01):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
[3]齐利琴,刘礼斌.GLP-1在2型糖尿病诱发的阿尔茨海默病治疗中的作用[J].国际内分泌代谢杂志,2016,36(01):48.[doi:10.3760/cma.j.issn.1673-4157.2016.01.012]
Qi Liqin,Liu Libin..Effects of GLP-1 in the treatment of Alzheimer's disease induced by type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2016,36(01):48.[doi:10.3760/cma.j.issn.1673-4157.2016.01.012]
[4]吴海洋,黄祯子,彭嘉欣,等.胰高血糖素样肽-1与肾素-血管紧张素系统的交互作用[J].国际内分泌代谢杂志,2016,36(05):312.[doi:10.3760/cma.j.issn.1673-4157.2016.05.07]
Wu Haiyang,Huang Zhen-zi,Peng Jiaxin,et al.Interaction between glucagon-like peptide-1 and renin angiotensin system[J].International Journal of Endocrinology and Metabolism,2016,36(01):312.[doi:10.3760/cma.j.issn.1673-4157.2016.05.07]
[5]韩丽萍,陈莉明.GLP-1的神经保护作用[J].国际内分泌代谢杂志,2016,36(05):316.[doi:10.3760/cma.j.issn.1673-4157.2016.05.08]
Han Liping,Chen Liming.Neuroprotective actions of glucagon-like peptide-1[J].International Journal of Endocrinology and Metabolism,2016,36(01):316.[doi:10.3760/cma.j.issn.1673-4157.2016.05.08]
[6]林楚曼 林伟浩 周蕊 杨力.GLP-1缓解非酒精性脂肪性肝病相关信号通路的研究进展[J].国际内分泌代谢杂志,2018,38(03):179.[doi:10.3760/cma.j.issn.1673-4157.2018.03.009]
Lin Chuman*,Lin Weihao,Zhou Rui,et al.The research progresses on GLP-1 related signal pathways in alleviating non-alcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2018,38(01):179.[doi:10.3760/cma.j.issn.1673-4157.2018.03.009]
[7]阮莹莹 闫彩凤.GLP-1对2型糖尿病患者骨骼的影响[J].国际内分泌代谢杂志,2018,38(04):275.[doi:10.3760/cma.j.issn.1673-4157.2018.04.014]
Ruan Yingying,Yan Caifeng..The impact of GLP-1 on bone in patients with type 2 diabetes[J].International Journal of Endocrinology and Metabolism,2018,38(01):275.[doi:10.3760/cma.j.issn.1673-4157.2018.04.014]
[8]王永 乐岭.GLP-1对血管重构中血管平滑肌细胞的影响[J].国际内分泌代谢杂志,2018,38(01):23.[doi:10.3760/cma.j.issn.1673-4157.2018.01.006]
Wang Yong,Yue Ling.Effects of GLP-1 on vascular smooth muscle cells in vascular remodeling[J].International Journal of Endocrinology and Metabolism,2018,38(01):23.[doi:10.3760/cma.j.issn.1673-4157.2018.01.006]
[9]刘国敏,刘学军.下丘脑血糖感应系统缺陷与2型糖尿病的关系[J].国际内分泌代谢杂志,2021,41(06):641.[doi:10.3760/cma.j.cn121383-20210805-08014]
Liu Guomin,Liu Xuejun..Association between hypothalamic glucose-sensing system dysfunction and type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2021,41(01):641.[doi:10.3760/cma.j.cn121383-20210805-08014]
[10]史雨清,杨昱,李宸,等.Tirzepatide:一种新型GLP-1/GIP双受体激动剂[J].国际内分泌代谢杂志,2021,41(06):645.[doi:10.3760/cma.j.cn121383-20200924-09046]
Shi Yuqing,Yang Yu,Li Chen,et al.Tirzepatide:a novel GLP-1/GIP dual receptor agonist[J].International Journal of Endocrinology and Metabolism,2021,41(01):645.[doi:10.3760/cma.j.cn121383-20200924-09046]